Computational reduction vaccine for Covid-19 Bin75

Abstract

A vaccine candidate is herein described comprised by statistically significant DNA fragments resulting in three types of compositions: 1) a composition of statistically significant DNA fragments, 2) a composition of RNA transcripts corresponding to the statistically significant DNA fragments, and 3) a computational reduction composition wherein the DNA fragments are fully or partially subtracted from a base organism, resulting in a synthetic organism which has a high statistical likelihood of problematic functions being partially or fully removed.

Claims

1. A composition comprised of statistically significant DNA fragments consisting of the sequences of SEQ ID NOs: 1-18 encapsulated in an appropriate delivery system.

2. A composition comprised of statistically significant mRNA fragments consisting of the sequences of SEQ ID NOs: 19-36 encapsulated in an appropriate delivery system.

3. A composition comprising a SARS-CoV-2 particle comprising the genome represented by SEQ ID NO: 37, where one or more of SEQ ID NOs: 1-18 have been removed from the genome.

Description

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

(1) FIG. 1 is a table of computational fragment reductions from Covid-19 which are between 75 and 99 base pairs. From left to right, you have the SEQ ID indicating the sequence ID in the sequence file; “Bin” size, or size of the fragments; the number of appearances of the fragment across the entire Covid-19 database; the appearance percent of the fragment expressed as a decimal; the Record ID for the reference organism in which the fragment was first found; the “strip” or fragment which when removed from a Covid-19 Super Organism or Base Organism will give us a vaccine; and the location of the fragment in the “Base Organism” file SEQ ID NO: 38.

(2) FIG. 2 is a SnapGene circular view of Covid-19 sample MT607247.1 from which this vaccine is derived.

(3) FIG. 3 is the same SnapGene circular view of MT607247.1 with the fragments removed.

DETAILED DESCRIPTION OF THE INVENTION

(4) There are several types of vaccines. This invention introduces a new type of vaccine which is a computationally derived reductive vaccine. A computationally derived reductive vaccine utilizes statistical computation to arrive at a list of fragments which can then be removed from live viruses or bacteria via Crispr to arrive at “neutered” versions which can then form the basis for the vaccine.

(5) Computational reduction in this case may be defined as non-laboratory computational reduction of organisms into fragments, which then can be assessed on the basis of frequency across an entire range of similar organisms as well as computationally tested to confirm that those structures are unique to the virus or bacteria in question. The particulars of the method of discovery for these fragments is proprietary.

(6) What is not proprietary is the statistical analysis of the fragments which are outlined in FIG. 1 and below. In the case of this particular vaccine candidate, the fragments which are included are between 75 and 99 base-pairs and appear in the NIH Covid-19 database greater than 66% of the time. The Covid-19 database “snapshot” from which the fragments in this patent were selected was taken on Jun. 16, 2020 at 5:21 am. That database is available upon request.

(7) The result of this patent is relatively simple. When a “Super Organism” or Covid-19 sample which contains all, or most, of the fragments outlined below is found, that Super Organism can then be genetically modified in a laboratory using Crispr to remove those fragments. Once all those fragments are removed from the organism, it can then be tested to see if problematic function remains. “Problematic function” in the case of Covid-19 is two-fold: functions of the virus which cause high transmissibility rates, and functions of the virus which cause high mortality rates. It may take us years to figure out exactly what those functions are and where they appear exactly on the genetic assay. This patent provides a shortcut by simply removing all of the most likely candidates for those problematic functions by identifying fragments which appear often enough not to be considered mutations (i.e. fragments only appearing in one or two samples).

(8) The scan of the entire database of Covid-19 provides 18 fragments between 75 and 99 base pairs which appear more than 66% of the time across the entire database. These fragments are unique to Covid-19 and cannot be found in any other virus in the NIH GenBank databases.

(9) In creation of the vaccine candidate we can also view that vaccine not only as a reductive entity (a library of removable fragments) which can be manufactured from a variety of possible starting organisms, but also as a complete organism which has potentially been “neutered” of its destructive features.

(10) In order to arrive at that possibility, we must first find a Covid-19 sample which contains all of these structures. Of the 3,938 complete Covid-19 sequences in the Jun. 16, 2020 Covid-19 database, 2,417 contain all 18 fragments. When computationally reduced, some fragments overlap, meaning those 2,417 samples which contain the fragments also had a maximum removal rate of 13 of 18 fragments.

(11) So to create a reductive vaccine, computationally those fragments are removed to create the vaccine candidate as shown in SEQ ID NO: 37. The original reference sequence can be downloaded from NIH via the reference MT607247.1. As previously stated, there are also 2,417 other reference candidates which could be used as Super Organisms or Base Organisms for the next generation of vaccines. That list is available upon request.

(12) This application also seeks to cover the RNA transcript of each of the fragments. (SEQ ID. NOs: 19-36). It may well be that RNA transcript vaccines based on these fragments would be of equal or greater efficacy in triggering a useful immune response.

(13) It should also be noted that these fragments are 75 base pairs or greater, which means a fragment has only a 1 in 1.60 quattuordecillion (4.sup.75) chance of occurring—in the entire history of the planet. In other words, even at a 66% recurrence rate across the entire Covid-19 genome, these fragments represent viable mathematical targets for vaccines.

(14) This application identifies 18 such fragments.